U.S. Capital Markets Stock News

Why Endava is back on investors’ radar Endava (DAVA) is drawing fresh attention after recent commentary highlighted slower revenue growth, cautious enterprise customer spending, conservative guidance, and a more measured view of its longer term growth prospects. See our latest analysis for Endava. That cautious tone has been reflected in Endava’s recent trading, with a 1 day share price return of 10.24% decline and a 90 day share price return of 36.9% decline. The 1 year total shareholder...

If you are wondering whether Thermo Fisher Scientific's current share price reflects its long term potential, you are not alone. This article will help you frame what the recent moves might mean for value focused investors. The stock last closed at US$570.09, with returns of an 8.6% decline over the past 7 days, a 3.8% decline over the past month, and a 3.8% decline year to date, while the 1 year return is a 1.5% decline and the 5 year return stands at 18.1%. Recent share price moves have...

If you are wondering whether Madrigal Pharmaceuticals' current share price reflects its true worth, this article will walk through what the numbers are saying about value. The stock last closed at US$482.45, with a 7 day return of a 3.6% decline, a 30 day return of an 18.8% decline and a year to date return of an 18.8% decline, while the 1 year return sits at 49.4%, the 3 year return at 75.4% and the 5 year return at 285.3%. Recent attention on Madrigal Pharmaceuticals has centered on...

Moog Inc. reported strong first-quarter 2026 results on January 30, 2026, with sales rising to US$1,100.35 million and net income increasing to US$78.85 million, alongside higher earnings per share, a raised full-year sales outlook to US$4.3 billion, and a quarterly dividend lifted to US$0.30 per share. These moves, combined with the completion of a multi-year share repurchase program and ongoing confidence in aerospace and defense demand, signal management’s willingness to return cash to...

Cogent Biosciences (COGT) recently reported two closely linked FDA milestones for its lead cancer therapy, and those regulatory updates are now central to how many investors are thinking about the stock. See our latest analysis for Cogent Biosciences. The FDA’s Breakthrough Therapy Designation and Real-Time Oncology Review decision arrived after a period of very strong market interest, with the share price at $37.28 and a 90 day share price return of 158.53%. The 1 year total shareholder...

If you are wondering whether Incyte's current share price lines up with its underlying worth, you are not alone. This article is designed to help you connect the dots between price and value. Incyte's share price recently closed at US$100.92, with returns of a 2.5% decline over 7 days, a 0.5% decline over 30 days, a 0.5% decline year to date, and a 36.2% gain over the past year, which hints at shifting expectations about the stock. Recent headlines around Incyte have focused on the company's...

Garmin (NYSE:GRMN) has introduced the Varia RearVue 820 radar tail light for cyclists. The product adds vehicle tracking, dynamic threat level alerts, and customizable lighting modes focused on rider safety. The launch expands Garmin's cycling safety technology lineup within its fitness and outdoor segment. For investors watching Garmin, the Varia RearVue 820 sits squarely in the company’s core fitness and outdoor business, where connected devices and safety features are an important part...

Key Insights Given the large stake in the stock by institutions, Ambarella's stock price might be vulnerable to their...

New Oriental Education & Technology Group recently reported past second-quarter fiscal 2026 results showing higher sales and net income, issued revenue guidance projecting further year-over-year growth for the third quarter and full year, and completed a US$86.3 million repurchase of 1,600,000 shares representing 1.01% of its share base. The combination of improving profitability, management’s outlook for continued revenue expansion, and capital returned through completed buybacks highlights...

Why Arcellx Stock Is Back in Focus After New CAR T Data Arcellx (ACLX) is back on investors’ radar after late breaking data on its D Domain binder in anitocabtagene autoleucel was accepted for presentation at the 2026 Tandem Meetings. The abstract centers on preclinical comparisons of different BCMA targeted CAR T constructs, highlighting how binder design may affect specificity, safety signals, and cytokine release in multiple myeloma treatment. For investors, this development relates less...

If you are wondering whether Champion Homes is starting to look like value after a weak share price patch, this article will walk through what the current price might be implying about the business. The stock last closed at US$76.03, with returns of an 11.8% decline over 7 days, a 10.5% decline over 30 days, a 10.5% decline year to date, but a 10.5% gain over 3 years and an 81.1% gain over 5 years. This mix of short term weakness and longer term gains can leave investors questioning whether...

Scholar Rock Holding's Chief Scientific Officer has executed multiple insider share sales under a pre-arranged 10b5-1 trading plan. The transactions come as the company readies apitegromab, its muscle-targeted treatment, for potential launch in the U.S. and Europe pending regulatory approvals. The timing links leadership share activity with a period of important commercialization preparations for the company. Scholar Rock Holding (NasdaqGS:SRRK) is drawing fresh attention as insider trading...

China Yuchai International recently reported that its earnings grew 29% over the past year, outpacing the broader machinery industry while advancing investments in new energy solutions and OEM partnerships. An interesting aspect of this update is the company’s balance sheet strength, with cash exceeding total debt, which may support ongoing technology investments. Next, we’ll examine how this combination of earnings growth and new energy investment shapes China Yuchai International’s broader...

Why Laureate Education is on investors’ radar today Laureate Education (LAUR) has drawn fresh attention after recent trading data highlighted its share performance over the past month and past 3 months, prompting investors to reassess the higher education provider’s current valuation. See our latest analysis for Laureate Education. The recent 90 day share price return of 12.17%, alongside a 1 year total shareholder return of 78.19% and very large 5 year total shareholder return, suggests...

Investors may be wondering whether Selective Insurance Group is attractively priced right now or if the recent attention has moved it away from a fair entry point. The stock last closed at US$86.82, with returns of 7.7% over the past week, 4.0% over the last month, 4.0% year to date, 6.0% over 1 year, negative 11.6% over 3 years, and 41.6% over 5 years, which gives a mixed picture of recent and longer term performance. Recent news coverage around Selective Insurance Group has centered on its...

Triumph Financial (TFIN) is back in focus after reporting full year 2025 results that topped Wall Street expectations, supported by cost discipline, a growing payments business, and new freight clients such as J.B. Hunt. See our latest analysis for Triumph Financial. The recent earnings beat and new freight partnerships have come alongside a 90 day share price return of 19.66%, while the 1 year total shareholder return decline of 15.82% shows longer term momentum has yet to catch up. If...

If you are asking yourself whether Analog Devices at around US$311 per share looks expensive or reasonable, you are not alone. That is exactly what this article will help unpack. The stock has recently delivered returns of 2.5% over the last 7 days, 13.7% over the last 30 days, 13.7% year to date and 53.6% over the past year, with longer term returns of 81.2% over 3 years and 122.2% over 5 years. These moves have come alongside ongoing interest in the semiconductor space and continuing...

In recent months, Progress Software has drawn attention for its acquisition-driven expansion, highlighted by the October 2024 purchase of ShareFile from Citrix for US$875 million, which lifted the company’s leverage above 3.5x and put more emphasis on future organic performance. This shift has raised questions about the balance between acquisition-led growth and underlying cash generation as investors assess how Progress Software will run the business with higher debt and tougher...

If you are wondering whether Agnico Eagle Mines is attractively priced after its strong run, this article walks through how the market might be valuing the stock today. The share price recently closed at US$197.35, with returns of 15.8% over the last 30 days and 109.1% over the past year, despite an 8.7% decline over the last week. Recent news around Agnico Eagle Mines has focused on its position in the gold mining sector, including commentary on how gold producers are reacting to shifts in...

In January 2026, Archera announced it had expanded its relationship with Ingram Micro, extending access to its cloud cost optimization and Insured Commitment offerings across Ingram Micro’s cloud service provider, reseller, and MSP network in the US and Canada. The move deepens joint go-to-market efforts and executive alignment, positioning Ingram Micro more firmly within the growing FinOps ecosystem for cloud customers. Next, we will consider how this broader FinOps-focused partnership with...

Trex Company (TREX) has been in focus after reporting third quarter results that included 22% net sales growth, 33% adjusted EBITDA growth, lower full year 2025 guidance, and plans for production cuts and inventory normalization. See our latest analysis for Trex Company. The recent quarterly update and softer Repair & Remodel backdrop come after a sharp reset in investor expectations. The 30-day share price return of 18.39% and 90-day share price return of 30.80% sit against a 1-year total...

Air Products and Chemicals (NYSE:APD) has secured major liquid hydrogen supply contracts with NASA. The agreements reinforce APD's role as a key supplier for existing and future NASA space missions. The contracts highlight APD's capabilities in clean hydrogen solutions for aerospace and energy applications. For you as an investor, this news sits at the intersection of space and clean energy, two areas getting a lot of attention. Air Products and Chemicals, a large industrial gases company,...

Paramount’s latest announcements confirm that Scream 7 will become the franchise’s first-ever IMAX release with early fan screenings, while director S.S. Rajamouli has cited an IMAX nature documentary as a key visual inspiration for his upcoming epic Varanasi, slated for theatrical release in 2027. Together, these developments highlight IMAX’s growing role in shaping both blockbuster franchise releases and the creative ambitions of high-profile filmmakers. Against this backdrop, we’ll...

As the United States stock market kicks off February with a strong performance, marked by significant gains in major indices like the Dow Jones Industrial Average and the S&P 500, investors are keenly observing opportunities amidst fluctuating economic signals. In this vibrant market environment, identifying undervalued stocks can be particularly appealing as they offer potential value when trading below their intrinsic worth.